Poster #01048

tt. t. r. - r. t. r. t. r. t. Pseudomonas aeruginosa . t. r t. t. t. .

rtr, r. trt, r. , r. , t. r JMI Laboratories, North Liberty, IA, USA

Introduction

- Meropenem-vaborbactam (MVB) is a combination of a carbapenem and a carbapenemase inhibitor developed to inhibit serine carbapenemases, such as KPC.
- MVB is approved in Europe for the treatment of complicated urinary tract infection (cUTI), including acute pyelonephritis, complicated intra-abdominal infection (cIAI), hospitalacquired bacterial pneumonia (HAP), ventilator-associated pneumonia (VAP), and bacteremia (BSI) associated with any of the infections listed above.
- This study examined the activity of MVB and comparators a collected from patients hospitalized against *P. a* with pneumonia in Europe during 2016–2020.
- Isolates from patients in the intensive care unit (ICU) and those with VAP were analysed as subsets, as were Eastern vs. Western European isolates.

Results

- a was the most common Gramnegative pathogen isolated from patients hospitalized with pneumonia for all patients, ICU patients, and patients with VAP (Figure 1).
- The susceptibilities of meropenem-vaborbactam and its

coloring a bartomy it for talking is an anti-source and the coloring and t

To obtain a PDF of this poster: Scan the QR code or visit https:// 345 Beaver Kreek Centre, Suite A Pneumonia.pdf

Dee Shortridge

North Liberty, Iowa 52317

Phone: 319-665-3370

www.jmilabs.com/data/posters/ECCMID2021_MeroVaborVEuro Charges may apply. No personal Email: dee-shortridge@jmilabs.com

information is stored.